Abstract : Trimetazidine Dihydrochloride is chemically known as 1-(2, 3, 4-trimethoxybenzyl) piperazine. It is a safe drug in the treatment of chronic ischemic disorders. So, for achieving continuous and constant plasma levels it is import to change immediate release dosage form into a modified release dosage form of Trimetazidine Dihydrochloride. The experiment revealed that Methocel K4M CR in varying concentrations control the Trimetazidine Dihydrochloride release effectively for 8 hours; hence the formulation F4 can be considered as the desired formulation for a twice daily sustained release tablet of trimetazidine dihydrochloride. Drug release kinetics indicated that the drug release of formulation F-1, F-2 and F-3 were best explained by First Order pot as the plot showed the highest value of linearity and the drug release of formulation F-4 and F-5 was best explained by First Order, Higuchi and Hixson-Crowell equations as these plots showed the highest value of linearity. Formulation F-6 to F-8 was best fitted in terms of Higuchi model. Kinetic modeling of in vitro dissolution profiles revealed the drug release mechanism from all proposed formulations (F-1 to F-8) showed exponent n values ranging from 0.358 to 0.697 indicating that both Fickian diffusion (F1 to F3) and non-Fickian diffusion or anomalous transport (F-4 to F-8) as if n = 0.45 the release mechanism follows Fickian diffusion and if 0.45

Keyword : Trimetazidine Dihydrochloride, Matrix tablets